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Abstract
Background
The prevalence of, and risk factors for, herpes simplex virus type-1 (HSV-1) infection and
reactivation in older individuals are poorly understood.
Methods
This is a prospective population-based study among community-dwelling individuals aged
40–79 years, followed from 1993, formed as a random subsample of the UK-based EPIC-
Norfolk cohort. HSV-1 seropositivity was derived from immunoglobulin G measurements
and frequent oro-labial HSV reactivation was self-reported. We carried out two cross-sec-
tional studies using logistic regression to investigate childhood social and environmental
conditions as risk factors for HSV-1 seropositivity and comorbidities as risk factors for appar-
ent HSV oro-labial reactivation.
Results
Of 9,929 participants, 6310 (63.6%) were HSV-1 IgG positive, and 870 (of 4,934 seroposi-
tive participants with reactivation data) experienced frequent oro-labial reactivation. Being
born outside the UK/Ireland, contemporaneous urban living and having�4 siblings were
risk factors for HSV-1 seropositivity. Ever diagnosed with kidney disease, but no other
comorbidities, was associated with an increased risk of frequent HSV reactivation (adjOR
1.87, 95%CI: 1.02–3.40).
PLOS ONE | https://doi.org/10.1371/journal.pone.0215553 May 9, 2019 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Forbes H, Warne B, Doelken L, Brenner N,
Waterboer T, Luben R, et al. (2019) Risk factors for
herpes simplex virus type-1 infection and
reactivation: Cross-sectional studies among EPIC-
Norfolk participants. PLoS ONE 14(5): e0215553.
https://doi.org/10.1371/journal.pone.0215553
Editor: Michael Nevels, University of St Andrews,
UNITED KINGDOM
Received: January 18, 2019
Accepted: April 3, 2019
Published: May 9, 2019
Copyright: © 2019 Forbes et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The authors will
make the dataset available under a Data Transfer
Agreement to any bona fide researcher who wishes
to obtain the dataset in order to undertake a
replication analysis. The EPIC-Norfolk study
depends on data from NHS digital or its previous
equivalent bodies. NHS Digital do not allow the
sharing of data at individual record level without
having a data sharing agreement in place.
Researchers wishing to request data can contact
the EPIC-Norfolk Management Committee at
Department of Public Health and Primary Care,
Discussion
Apparent HSV-1 seropositivity and clinical reactivation are common within an ageing UK
population. HSV-1 seropositivity is socially patterned while risk factors for oro-labial HSV
reactivation are less clear. Further large studies of risk factors are needed to inform HSV-1
control strategies.
Introduction
HSV-1 is one of eight herpesviruses that routinely infect humans.[1] It is thought to be trans-
mitted via close contact in childhood and it establishes latency in sensory ganglia. HSV-1 reac-
tivation causes outbreaks of oro-labial, oropharyngeal, or increasingly, genital ulcers,[2] but
can also be asymptomatic. Oro-labial ulcers can also be caused by HSV-2 reactivation[3] and
the two viruses are clinically indistinguishable. However, oro-labial HSV-2 reactivation is very
infrequent.[3] The prevalence of HSV-1 infection varies by age, time and geographic setting,
with European seroprevalence estimates ranging from around 50–80%.[4] Following infection
only around 30% of individuals with serologic evidence of HSV-1 experience clinical reactiva-
tion[5] but the factors involved in infection susceptibility and control of latent infection are
poorly understood.
There is a growing interest in the role of chronic viruses in the pathogenesis of cardiovascu-
lar and neurodegenerative disorders affecting older individuals.[6, 7] Routinely collected
health data are increasingly being used to assess the effects of such viruses on chronic diseases.
However, HSV-1 is poorly recorded in routine health data so there is a need for population-
based cohorts with biological and social measures to provide updated estimates of infection
and reactivation. This will help both to plan public health interventions to control HSV-1
infection and guide the design of research studies of HSV-1 as a risk factor for other
conditions.
Using data from a community-dwelling, ageing UK cohort, we therefore aimed to investi-
gate the effect of childhood environmental and social conditions on the risk of HSV-1 seropos-
itivity at a single time point in adulthood, alongside the effects of common clinical exposures
and comorbidities of middle to later life on the risk of frequent self-reported HSV reactivation,
among those infected with HSV-1.
Methods
Ethics statement
All volunteers gave written informed consent, and the study was approved by the Norfolk
Research Ethics Committee (98CN01) and LSHTM ethics committee (14188).
Data source
The European Prospective Investigation of Cancer and Nutrition (EPIC) study design and
methods have been described in detail elsewhere.[8–10] In brief, EPIC is a multi-center pro-
spective cohort study and the EPIC-Norfolk cohort was recruited from the county of Norfolk
in the East of England.[8] Individuals aged between 40 and 79 years registered at participating
primary care practices were asked to join. Of 77,630 individuals invited to participate, 30,445
(39.2%) consented and 25,639 completed the first health check. Data collection is ongoing,
with information gathered through self-reported questionnaires, health checks, biological
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samples and linked electronic databases. A time line of the EPIC Norfolk follow-up is shown
in Fig 1.
All participants taking part in the first health check were invited to a second health check
(from 1998 onwards) and 15,786/25,639 (61.6%) of the original cohort attended. Blood and
urine samples were taken (described in detail previously[11]). From participants with available
sera, 10,000 samples were randomly selected for further analysis, including characterizing
HSV-1 and HSV-2 seropositivity (see Fig 1). Following the second health check, a third health
and lifestyle questionnaire was sent between 2002 and 2004 (herein referred to as the Follow 3
questionnaire).
Fig 1. Timeline of EPIC Norfolk data and diagram of study participants utilized in this study.
https://doi.org/10.1371/journal.pone.0215553.g001
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Outcome definitions
The primary outcomes of interest were HSV-1 seropositivity and HSV-1 reactivation. Quanti-
tative IgG antibody titres were determined using multiplex serology, an assay developed at the
German Cancer Research Center (DKFZ) in Heidelberg. All analyses and quality control pro-
cedures were performed at DKFZ. HSV-1 seropositivity was defined by the presence of two
positive antibody responses (above a pre-specified cut-off level) to the HSV-1 antigens gG and
gD. The cut-off level was 100 mean fluorescence intensity (MFI) units for each antigen, based
on visual inspection of turning points in percentile plots.[12] Both antigens are membrane gly-
coproteins important in virion attachment and entry into the host cell. The majority of the
humoral response to HSV infection is targeted at these antigens. Seronegative meant the sam-
ple had either one or both negative responses to HSV-1 antigens. Among seropositive patients
only, we created a categorical HSV-1 seropositivity variable by grouping participants into
thirds of the antibody titre distribution (as there is no standard categorical definition of HSV-1
IgG titre levels). In the Follow 3 questionnaire participants were asked, “Are there any other
infections which you commonly get more than once or twice a year?”, of which cold sores
were specified as one option. This question therefore captures those with “frequent” HSV reac-
tivation, defined as�2 reactivations per year.
In a further post-hoc sensitivity analysis we used a secondary definition of our outcomes,
using single antigens to define HSV-1 (anti-gG response to HSV-1 is�300 MFI) and HSV-2
(anti-mgGunique response to HSV-2�300 MFI) seropositivity; this was to reduce the theoret-
ical risk of antibody cross-reactivity with the gD antigens. The 300 MFI cutoff was determined
using Receiver Operating Characteristic curves produced by comparing the multiplex assay
with the Enzygnost Anti-HSV/IgG (Dade Behring Marburg GmbH, Marburg, Germany)
ELISA in 203 clinical samples processed at the Heidelberg diagnostic laboratory.
Primary exposure definitions
All exposures below were self-reported, unless otherwise specified.
Childhood environmental and social conditions included: country of birth (as a proxy mea-
sure of background HSV-1 infection levels) at the second health check; socioeconomic status
of household (with Townsend area deprivation indices derived from the 1991 census data, and
categorised according to national Townsend quintiles from 1991[13]) and level of urbanisation
at birth (using 1991 census data on level of urbanisation as a proxy); number of siblings (as a
proxy measure of house hold density and degree of close contact) and measures of childhood
health (including spending two weeks in hospital as a child and low birthweight) from the first
health-check.
Common clinical comorbidities of middle to later life with an emphasis to any possible
immunosuppressive medication use or condition were selected from the information collected
via the Follow 3 questionnaire. Medications included corticosteroid use, other immunosup-
pressive medications (for example chemotherapy and methotrexate) and non-steroidal anti-
inflammatory drugs, all derived from free-text data. Conditions included cancer (excluding
non-melanoma skin cancer) externally derived from ICD-coded cancer registry data[8] prior
to date of the third follow-up questionnaire. It also included the following conditions, which
participants were asked whether their doctor had ever told them they had: rheumatoid arthri-
tis, ulcerative colitis and/or Crohn’s disease, kidney disease (e.g. nephritis) and diabetes.
Other exposures
We studied other exposures that could be associated with HSV reactivation based on previ-
ously published studies, including: age (in 10 year bands, as there was no evidence of non-
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linearity) and smoking status (current, former, never) derived from the second health check or
Follow 3 questionnaire); body mass index (BMI: grouped according to World Health Organi-
zation categories), concentration of 25-hydroxyvitamin D3 (nmol/L) and HSV-2 seropositivity
derived from the second health check (a positive gD antibody response to HSV-2 and positive
to mgGunique antigen (both above a cut-off level of 100 MFI[12])); gender, ethnicity, highest
educational qualification, having had an outdoor job (as a proxy measure of sunlight expo-
sure), stress (from the question, “Has stress affected your health?”) derived from the first health
check; and fatigue (from the question, “Do you feel tired all the time?”) from the Follow 3
questionnaire.
Design and statistical analysis plan
We first described the characteristics of each cohort of interest. The first cohort comprised all
those with HSV-1 serology data; the second cohort comprised HSV-1 seropositive individuals
with data on oro-labial HSV reactivation. We explored whether the study participants in each
cohort were representative of the main EPIC Norfolk cohort, in terms of age, gender, anthro-
pometry, smoking status and blood pressure at baseline. We went on to carry out two cross
sectional studies to understand the determinants of HSV-1 infection and frequent HSV
reactivation.
The first study assessed the determinants of HSV-1 infection in the first cohort. The pri-
mary exposures of interest were childhood environmental and social conditions. Logistic
regression was used to generate crude odds ratios to estimate the strength of association of
each exposure with HSV-1 seropositivity, as well as adjusted odds ratios accounting for poten-
tial confounders. Our first model adjusted for ethnicity and gender, according to our causal
assumptions (see causal diagram[14] in S1 Fig). We did not adjust for number of siblings
because this may lie on the causal pathway. In a sensitivity analysis we additionally adjusted
for HSV-2 seropositivity and age at the time of serology sampling.
The second cross sectional study examined the determinants of frequent HSV reactivation
in the second cohort (see Fig 1). The primary exposures were common clinical comorbidities
of middle to later life. Logistic regression was used to generate crude odds ratios to estimate
the strength of association of each exposure with HSV reactivation as well as adjusted odds
ratios, accounting for potential confounders. In our first model we adjusted for gender, age,
ethnicity, SES, lifestyle risk factors (smoking, alcohol and BMI) and psychological stress,
according to our causal assumptions (see causal diagram S1 Fig). In a sensitivity analysis we
additionally adjusted for HSV-2 seropositivity, a proxy for UV light exposure and fatigue. A-
priori we hypothesized age may modify the association between our primary exposures and
frequent HSV reactivation, therefore we stratified our results by older and younger partici-
pants (using median age as the cut-off point). We also hypothesised frequency of cold sores
and/or reporting of cold sores may differ by gender, therefore we stratified our results by
gender.
All analyses were carried out in STATA, version 14.2 (College Station, TX).
Results
In total 9,929 participants had HSV-1 serology data (first cohort) and 6,310 (64%) were sero-
positive for HSV-1 (Table 1). Of these seropositives, 4,934 participants (78%) had HSV reacti-
vation data (second cohort—see Fig 1). The cohort was born between 1914 and 1957 and the
median age of both cohorts was 62 years (IQR: 54–69) when serology specimens were col-
lected. Compared to the main EPIC Norfolk cohort who attended the first health check, both
Herpes simplex virus type 1 epidemiology
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Table 1. Description of the first cohort, prevalence of HSV-1 infection and association between each variable and HSV-1 infection.
Variable (source of data) Overall n
(%)
Prevalence HSV-1+ n
(%)
Unadjusted OR (95%
CI)
Fully adjusted� OR
(95% CI)
Sensitivity analysis: adjusted�� OR
(95% CI)
No of participants 9929
(100%)
6310 (63.6) - - -
Demographic characteristics
Gender (1HC)
Males 4047 (40.8) 2531 (62.5) 1 1 1
Females 5882 (59.2) 3779 (64.2) 1.08 (0.99–1.17) 1.08 (0.99–1.17) 1.09 (1.00–1.19)
Age in years (2HC)
40–49 659 (6.6) 361 (54.8) 1 1 1
50–59 3518 (35.4) 2084 (59.2) 1.20 (1.01–1.42) 1.21 (1.02–1.43) 1.24 (1.05–1.47)
60–69 3334 (33.6) 2181 (65.4) 1.56 (1.32–1.85) 1.58 (1.34–1.88) 1.65 (1.39–1.97)
70–79 2352 (23.7) 1640 (69.7) 1.90 (1.59–2.27) 1.94 (1.62–2.31) 2.02 (1.68–2.41)
80–89 66 (0.7) 44 (66.7) 1.65 (0.97–2.82) 1.68 (0.98–2.86) 1.75 (1.02–3.00)
Ethnicity (1HC)
White 9863 (99.3) 6263 (63.5) 1 1 1
Other 66 (0.7) 47 (71.2) 1.42 (0.83–2.43) 1.43 (0.84–2.45) 1.52 (0.88–2.61)
Missing 33 (0.3)
Highest educational qualification achieved (1HC)
None 3316 (33.4) 2330 (70.3) 1 1 1
O-Level 1090 (11.0) 682 (62.6) 0.71 (0.61–0.82) 0.71 (0.61–0.82) 0.75 (0.65–0.87)
A-level 4110 (41.4) 2539 (61.8) 0.68 (0.62–0.75) 0.69 (0.62–0.76) 0.72 (0.65–0.80)
Degree or higher 1410 (14.2) 757 (53.7) 0.49 (0.43–0.56) 0.49 (0.43–0.56) 0.53 (0.46–0.60)
Missing 103 (1.0)
Health characteristics
BMI category (2HC)
Underweight 41 (0.4) 21 (51.2) 0.66 (0.36–1.23) 0.64 (0.35–1.19) 0.68 (0.37–1.26)
Normal Weight 3623 (36.5) 2222 (61.3) 1 1 1
Overweight 4630 (46.6) 2953 (63.8) 1.11 (1.01–1.21) 1.13 (1.03–1.23) 1.09 (0.99–1.20)
Obese 1619 (16.3) 1104 (68.2) 1.35 (1.19–1.53) 1.36 (1.20–1.54) 1.29 (1.13–1.46)
Missing 16 (0.2)
Smoking status (2HC)
current smoker 739 (7.4) 514 (69.6) 1 1 1
former smoker 4201 (42.3) 2818 (67.1) 0.89 (0.75–1.06) 0.92 (0.77–1.09) 0.87 (0.73–1.04)
never smoked 4915 (49.5) 2927 (59.6) 0.64 (0.55–0.76) 0.64 (0.54–0.75) 0.64 (0.54–0.76)
Missing 74 (0.8)
HSV-2 serostatus
negative 9574 (96.4) 5964 (62.3) 1 1 1
positive 355 (3.6) 346 (97.5) 23.27 (11.99–45.16) 23.10 (11.90–44.83) 24.05 (12.38–46.70)
Sociodemographic and childhood
characteristics
Country of birth (2HC, F3)
UK and Ireland 7702 (77.6) 4816 (62.5) 1 1 1
Other European country 96 (1.0) 73 (76.0) 1.90 (1.19–3.05) 1.88 (1.17–3.01) 1.70 (1.05–2.74)
US, Canada, Australia and NZ 40 (0.4) 19 (47.5) 0.54 (0.29–1.01) 0.54 (0.29–1.01) 0.46 (0.24–0.88)
Asia, S. America, Africa, Middle East 99 (1.0) 57 (57.6) 0.81 (0.54–1.21) 0.74 (0.48–1.13) 0.67 (0.43–1.04)
Missing 1992 (20.1)
Level of urbanisation (1991 census data)
Urban 4536 (45.7) 2968 (65.4) 1 1 1
(Continued)
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the first and second cohort were more likely to be female and less likely to be>75 years, over-
weight and obese, current and former smokers and have high blood pressure (see S1 Table).
The risk of HSV-1 seropositivity (Table 1) was almost 2-fold greater for those born in
another European country (compared to the UK and Ireland), 10–20% lower for those residing
in towns or hamlets at the time of 1991 census (compared to urban areas), almost 3-fold
greater for those in the lowest socioeconomic quintile (compared to the highest), and almost
2-fold greater for those with four or more siblings (compared to one). Self-reported childhood
illness (warranting�2 weeks in hospital) was weakly associated with increased risk of HSV-1
seropositivity (adjOR 1.10, 95%CI 0.99–1.22). There was no evidence that having a low birth-
weight (<2.5kg) was associated with increased risk of HSV-1 seropositivity, though this vari-
able had a considerable amount of missing data (55.4%). Being older, female, having lower
educational achievement, being obese and a current or former smoker were associated with
increased risk of HSV-1 seropositivity.
Of the 6,310 participants identified as HSV-1 seropositive, 4,934 (78%) had available infor-
mation on oro-labial reactivation. Of these, 870 (17.6%) reportedly experienced frequent HSV
Table 1. (Continued)
Variable (source of data) Overall n
(%)
Prevalence HSV-1+ n
(%)
Unadjusted OR (95%
CI)
Fully adjusted� OR
(95% CI)
Sensitivity analysis: adjusted�� OR
(95% CI)
Town 2159 (21.7) 1355 (62.8) 0.89 (0.80–0.99) 0.89 (0.80–0.99) 0.89 (0.80–0.99)
Village 2319 (23.4) 1465 (63.2) 0.91 (0.82–1.01) 0.91 (0.82–1.01) 0.93 (0.84–1.03)
Hamlet 910 (9.2) 519 (57.0) 0.70 (0.61–0.81) 0.70 (0.61–0.81) 0.73 (0.63–0.84)
Missing 5 (0.05)
Townsend quintile (1HC)1
Q1 (most affluent) 5667 (57.1) 3555 (62.7) 1 1 1
Q2 2518 (25.4) 1591 (63.2) 1.02 (0.93–1.12) 1.02 (0.92–1.12) 1.02 (0.93–1.13)
Q3 1077 (10.8) 690 (64.1) 1.06 (0.92–1.21) 1.06 (0.92–1.21) 1.06 (0.93–1.22)
Q4 553 (5.6) 385 (69.6) 1.36 (1.13–1.64) 1.35 (1.12–1.64) 1.32 (1.09–1.60)
Q5 (most deprived) 84 (0.8) 70 (83.3) 2.97 (1.67–5.29) 2.97 (1.67–5.28) 2.97 (1.66–5.30)
Missing 30 (0.3)
Number of siblings (1HC)
0 1204 (12.1) 713 (59.2) 1.03 (0.90–1.19) 1.03 (0.90–1.19) 1.02 (0.88–1.18)
1 2398 (24.2) 1402 (58.5) 1 1 1
2 2141 (21.6) 1309 (61.1) 1.12 (0.99–1.26) 1.12 (0.99–1.26) 1.10 (0.97–1.24)
3 1372 (13.8) 867 (63.2) 1.22 (1.06–1.40) 1.22 (1.06–1.40) 1.21 (1.06–1.39)
4 or more 2814 (28.3) 2019 (71.7) 1.80 (1.61–2.03) 1.80 (1.60–2.02) 1.76 (1.56–1.97)
Spent 2+ weeks in a hospital during childhood (HLEQ baseline)
No 6746 (67.9) 4237 (62.8) 1 1 1
Yes 1919 (19.3) 1245 (64.9) 1.09 (0.98–1.22) 1.10 (0.99–1.22) 1.07 (0.96–1.20)
Missing 1264 (12.7)
Low birth weight (1HC)
No 3897 (39.2) 2416 (62.0) 1 1 1
Yes (<2.5kg) 532 (5.4) 338 (63.5) 1.07 (0.88–1.29) 1.07 (0.88–1.29) 1.06 (0.87–1.29)
Missing 5500 (55.4)
�Adjusted for ethnicity and sex.
��Adjusted for ethnicity, sex, age and HSV-2 serostatus.
1Split according to cut-offs for England and Wales 1991. 1HC = First health check, 2HC = Second health check, F3 = Follow 3, HLEQ = Health and lifestyle
questionnaire.
https://doi.org/10.1371/journal.pone.0215553.t001
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reactivation (Table 2). Table 2 shows the association between frequent HSV reactivation and
exposures of interest. Kidney disease (reported by 61 participants) was associated with an
almost 2-fold increased risk of frequent reactivation (adjOR 1.87, 95%CI 1.02–3.40). No other
medical conditions or medications were associated with frequent reactivation. There was some
evidence that having held an outdoor job (reported by 729 participants) was associated with
HSV reactivation (adjOR 1.33, 95% CI 1.06–1.67). However, concentration of Vitamin D3 was
not associated. Higher levels of fatigue and stress were associated with an increased risk of fre-
quent HSV reactivation. There was some weak evidence that HSV-2 seropositivity was associ-
ated with reduced risk of frequent HSV reactivation (adjOR 0.69, 95%CI 0.47–1.02).
Stratified results by age and sex are given in the supplementary material (S2 and S3 Tables).
Briefly, the increased risk of frequent HSV reactivation among participants with kidney disease
was restricted to participants�65 years of age (adjOR2.66, 95%CI 1.14–6.21) and also females
(adjOR2.43, 95%CI 1.23–4.81). By contrast, the increased risk of frequent HSV reactivation
among those with an outdoor job was restricted to males. HSV-2 seropositivity was associated
with a reduced risk of frequent HSV reactivation among females (adjOR 0.53, 95%CI:0.32–
0.89), but not among males (adjOR 1.15, 95%CI:0.61–2.14).
In our post-hoc sensitivity analysis HSV-1 and HSV-2 were redefined using single antigens.
Although the seroprevalence of HSV-1 increased markedly, the results for risk factors for
HSV-1 seropositivity were broadly the same as the main analyses, aside from there being no
evidence of a reduced risk of HSV-1 seropositivity for those living in a hamlet and the associa-
tion between HSV-1 and HSV-2 prevalence reduced dramatically (Table 3). In the risk factors
for HSV reactivation, the results were broadly similar, aside from there being a clearer dose-
response relationship between increased level of HSV-1 IgG and increased risk of HSV reacti-
vation (Table 4).
Discussion
In this cohort of older community-dwelling individuals from England, we found a high preva-
lence of HSV-1 seropositivity (63.6%) and frequent apparent reactivation (17.6%). We found
that childhood environmental and social conditions were associated with greater risk of HSV-
1 seropositivity, specifically poorer socioeconomic status, having more siblings and living in
an urban area. Common comorbidities were not associated with HSV reactivation with the
exception of kidney disease, which was associated with a 2-fold increased risk, an association
which was restricted to older females (�65 years). Fatigue and stress increased the risk of HSV
reactivation, as did having an outdoor job (an association restricted to males).
The prevalence of HSV-1 seropositivity in this cohort was similar to estimates in England
and Wales during the 1990s[4] as well as the proportion found to be seropositive in recently
released data from UK Biobank (~70%), which has a comparable population.[15] Data on
HSV-1 reactivation are less clear, with an estimated 12%[5] of HSV-1 infected people
experiencing two or more reactivations per year. The figure may be slightly higher in our
study, due to an older cohort and differing definitions of reactivation (one rather than two or
more cold sores per year).[16]
Many of the risk factors associated with HSV-1 seropositivity identified in this study are in
keeping with previous research, including increasing age [1, 17–19], lower educational level
and socioeconomic status[20]. Our study found increased prevalence with age up to 70 years,
after which the risk declined: this decline may reflect a cohort effect (that participants from
older generations may have been exposed to HSV-1 less than younger generations or that
those who reached 80 years are generally healthier and less susceptible to HSV-1). Non-white
ethnicity[1, 20, 21] has been associated with greater risk of HSV-1 infection, however this
Herpes simplex virus type 1 epidemiology
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Table 2. Description of the second cohort of HSV-1 positive individuals, prevalence of HSV reactivation and association between each variable and HSV
reactivation.
Overall n
(%)
Prevalence HSV
reactivation n (%)
Unadjusted OR
(95% CI)
Fully adjusted� OR
(95% CI)
Sensitivity analysis: adjusted��
OR (95% CI)
Number of participants 4934
(100%)
870 (17.6)
Demographic characteristics
Age in years (F3) 40–49 112 (2.3) 19 (17.0) 1 1 1
50–59 1164 (23.6) 238 (20.4) 1.26 (0.75–2.10) 1.19 (0.69–2.06) 1.24 (0.70–2.18)
60–69 1700 (34.5) 298 (17.5) 1.04 (0.63–1.73) 1.02 (0.59–1.77) 1.07 (0.61–1.88)
70–79 1550 (31.4) 261 (16.8) 0.99 (0.59–1.65) 1.03 (0.60–1.79) 1.09 (0.62–1.92)
80–89 397 (8.0) 50 (12.6) 0.71 (0.40–1.25) 0.66 (0.35–1.23) 0.68 (0.36–1.28)
Gender (1HC) Males 1940 (39.3) 321 (16.5) 1 1 1
Females 2994 (60.7) 549 (18.3) 1.13 (0.97–1.32) 1.07 (0.90–1.27) 1.11 (0.93–1.32)
Ethnicity (1HC) White 4899 (99.3) 866 (17.7) 1 1 1
Other 35 (0.7) 4 (11.4) 0.60 (0.21–1.71) 0.72 (0.21–2.46) 0.74 (0.21–2.59)
Education level (1HC) None 1722 (34.9) 296 (17.2) 1 1 1
O-Level 547 (11.1) 110 (20.1) 1.21 (0.95–1.55) 1.08 (0.83–1.41) 1.07 (0.82–1.41)
A-level 2027 (41.1) 355 (17.5) 1.02 (0.86–1.21) 0.97 (0.80–1.17) 0.98 (0.81–1.18)
Degree or higher 636 (12.9) 109 (17.1) 1.00 (0.78–1.27) 0.90 (0.69–1.18) 0.94 (0.72–1.23)
Missing 2 (0.04)
Townsend quintile (1HC)1 Q1 (most affluent) 2824 (57.2) 504 (17.8) 1 1 1
Q2 1246 (25.3) 220 (17.7) 0.99 (0.83–1.18) 0.97 (0.80–1.17) 0.95 (0.79–1.15)
Q3 530 (10.7) 80 (15.1) 0.82 (0.63–1.06) 0.81 (0.61–1.06) 0.78 (0.59–1.03)
Q4 278 (5.6) 58 (20.9) 1.21 (0.89–1.65) 1.28 (0.92–1.78) 1.28 (0.92–1.79)
Q5 (most
deprived)
43 (0.9) 7 (16.3) 0.90 (0.40–2.02) 1.25 (0.54–2.91) 1.33 (0.57–3.12)
Missing 13 (0.3)
Immunosuppressive medications and conditions
Corticosteroids (F3) No 4307 (87.3) 771 (17.9) 1 1 1
Yes 193 (3.9) 34 (17.6) 0.98 (0.67–1.43) 0.94 (0.62–1.42) 0.88 (0.58–1.34)
Missing 434 (8.8)
Immunosuppressive medications (F3) No 4875 (98.8) 860 (17.6) 1 1 1
Yes 59 (1.2) 10 (16.9) 0.95 (0.48–1.89) 0.89 (0.41–1.91) 0.83 (0.39–1.80)
NSAIDs (F3) No 3683 (74.6) 663 (18.0) 1 1 1
Yes 1251 (25.4) 207 (16.5) 0.90 (0.76–1.07) 0.94 (0.78–1.14) 0.92 (0.76–1.11)
Arthritis (2HC) No 3026 (61.3) 523 (17.3) 1 1 1
Yes 1509 (30.6) 273 (18.1) 1.06 (0.90–1.24) 1.16 (0.96–1.39) 1.09 (0.90–1.32)
Missing 399 (8.1)
Ulcerative Colitis / Crohn‘s Disease (F3) No 4540 (92.0) 810 (17.8) 1 1 1
Yes 75 (1.5) 14 (18.7) 1.06 (0.59–1.90) 1.00 (0.53–1.87) 1.00 (0.53–1.85)
Missing 319 (6.5)
Kidney Disease (F3) No 4579 (92.8) 812 (17.7) 1 1 1
Yes 61 (1.2) 17 (27.9) 1.79 (1.02–3.15) 1.87 (1.02–3.40) 1.87 (1.02–3.44)
Missing 294 (6.0)
Diabetes (2HC) No 4749 (96.3) 837 (17.6) 1 1 1
Yes 185 (3.7) 33 (17.8) 1.01 (0.69–1.49) 0.94 (0.60–1.46) 0.96 (0.62–1.51)
Cancer (from cancer registry data) No 4416 (89.5) 788 (17.8) 1 1 1
Yes 518 (10.5) 82 (15.8) 0.87 (0.68–1.11) 0.85 (0.65–1.12) 0.85 (0.65–1.12)
Other known risk factors for HSV reactivation
UV light exposure: had an outdoor job
(1HC)
No 4202 (85.2) 720 (17.1) 1 1 1
Yes 729 (14.8) 149 (20.4) 1.24 (1.02–1.51) 1.33 (1.06–1.67) 1.33 (1.06–1.67)
Missing 3 (0.1)
(Continued)
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cohort was predominately white (99.3%) and therefore unable to examine the effect of ethnic
group. Literature regarding gender is conflicting, with some papers suggesting female gender
[20, 22, 23] is associated with greater risk of HSV-1 infection, whilst others report no associa-
tion.[1, 24] The small increased risk of HSV-1 seropositivity with female sex we observed may
reflect different behaviours increasing opportunity for exposure, such as greater childcare
responsibilities. It may also reflect different immune response among females, or greater
genetic susceptibility to infection.
Table 2. (Continued)
Overall n
(%)
Prevalence HSV
reactivation n (%)
Unadjusted OR
(95% CI)
Fully adjusted� OR
(95% CI)
Sensitivity analysis: adjusted��
OR (95% CI)
Concentration of 25-Hydroxyvitamin D3
(nmol/L)(2HC)
Deficient (0–29) 507 (10.3) 73 (14.4) 0.76 (0.58–1.01) 0.79 (0.58–1.07) 0.79 (0.58–1.07)
Insufficiency (30–
49)
1492 (30.2) 254 (17.0) 0.93 (0.77–1.12) 1.02 (0.83–1.25) 1.02 (0.83–1.25)
Adequate (50–69) 1602 (32.5) 289 (18.0) 1 1 1
High (70–89) 887 (18.0) 177 (20.0) 1.13 (0.92–1.39) 1.17 (0.93–1.47) 1.17 (0.93–1.47)
Undesirably high
(90+)
428 (8.7) 73 (17.1) 0.93 (0.70–1.24) 0.98 (0.72–1.33) 0.98 (0.72–1.33)
Missing 18 (0.4)
Do you feel tired? (F3) All of the time 112 (2.3) 27 (24.1) 1.50 (0.96–2.34) 1.31 (0.78–2.21) 1.30 (0.77–2.19)
Most of the time 258 (5.2) 71 (27.5) 1.79 (1.33–2.41) 1.65 (1.19–2.28) 1.67 (1.20–2.31)
A good bit of the
time
551 (11.2) 107 (19.4) 1.14 (0.89–1.44) 1.02 (0.78–1.32) 1.01 (0.77–1.31)
Some of the time 2052 (41.6) 359 (17.5) 1 1 1
A little of the time 1617 (32.8) 272 (16.8) 0.95 (0.80–1.13) 0.95 (0.79–1.14) 0.95 (0.79–1.14)
None of the time 294 (6.0) 30 (10.2) 0.54 (0.36–0.80) 0.55 (0.36–0.84) 0.55 (0.36–0.85)
Missing 50 (1.0)
Has stress affected your health? (1HC) Not at all 1356 (27.5) 205 (15.1) 1 1 1
A little 1869 (37.9) 338 (18.1) 1.24 (1.03–1.50) 1.22 (1.01–1.48) 1.17 (0.96–1.42)
A moderate
amount
747 (15.1) 150 (20.1) 1.41 (1.12–1.78) 1.39 (1.10–1.76) 1.28 (1.00–1.63)
A great deal 363 (7.4) 76 (20.9) 1.49 (1.11–1.99) 1.45 (1.08–1.95) 1.28 (0.94–1.74)
Missing 599 (12.1)
Health characteristics
BMI category (2HC) Underweight 13 (0.3) 3 (23.1) 1.32 (0.36–4.83) 1.10 (0.23–5.29) 1.29 (0.27–6.24)
Normal Weight 1772 (35.9) 328 (18.5) 1 1 1
Overweight 2317 (47.0) 388 (16.7) 0.89 (0.75–1.04) 0.88 (0.73–1.05) 0.87 (0.73–1.04)
Obese 826 (16.7) 151 (18.3) 0.98 (0.80–1.22) 0.99 (0.79–1.25) 0.96 (0.76–1.21)
Missing 6 (0.1)
Smoking status (F3) Current smoker 371 (7.5) 50 (13.5) 0.69 (0.50–0.94) 0.61 (0.42–0.86) 0.56 (0.39–0.81)
Former smoker 2293 (46.5) 399 (17.4) 0.93 (0.80–1.08) 0.94 (0.79–1.11) 0.93 (0.78–1.10)
Never smoked 2244 (45.5) 415 (18.5) 1 1 1
Missing 26 (0.5)
HSV-2 infection No 4671 (94.7) 835 (17.9) 1 1 1
Yes 263 (5.3) 35 (13.3) 0.71 (0.49–1.01) 0.69 (0.47–1.02) 0.69 (0.47–1.03)
Level of HSV-1 IgG, in tertiles Low 1644 (33.3) 192 (11.7) 1 1 1
Medium 1645 (33.3) 342 (20.8) 1.98 (1.64–2.40) 2.10 (1.70–2.59) 2.08 (1.68–2.57)
High 1645 (33.3) 336 (20.4) 1.94 (1.60–2.35) 2.11 (1.71–2.60) 2.09 (1.69–2.59)
Missing 33 (0.3)
�Adjusted for gender, age, ethnicity, SES, lifestyle factors (smoking and BMI) and psychological stress
��Additionally adjusted for UV light exposure, fatigue and HSV-2 status. NSAIDs: Non-steroidal anti-inflammatories. 1HC = First health check, 2HC = Second health
check, F3 = Follow 3, HLEQ = Health and lifestyle questionnaire.
https://doi.org/10.1371/journal.pone.0215553.t002
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Table 3. Description of the first cohort, prevalence of HSV-1 infection defined using a single antigen and association between each variable and HSV-1 infection.
Variable (source of data) Overall n
(%)
Prevalence HSV-1+ n
(%)
Unadjusted OR (95%
CI)
Fully adjusted� OR (95%
CI)
Sensitivity analysis: adjusted�� OR
(95% CI)
No of participants 9929 (100S) 9073 (91.4) - - -
Demographic characteristics
Gender (1HC)
Males 4047 (40.8) 3676 (90.8)
Females 5882 (59.2) 5397 (91.8) 1.12 (0.97–1.29) 1.12 (0.98–1.29) 1.14 (0.99–1.31)
Age in years (2HC)
40–49 659 (6.6) 593 (90.0) 1.00 1.00 1.00
50–59 3518 (35.4) 3187 (90.6) 1.07 (0.81–1.42) 1.08 (0.81–1.42) 1.08 (0.82–1.43)
60–69 3334 (33.6) 3038 (91.1) 1.14 (0.86–1.51) 1.16 (0.87–1.54) 1.17 (0.88–1.55)
70–79 2352 (23.7) 2194 (93.3) 1.55 (1.14–2.09) 1.57 (1.16–2.13) 1.58 (1.17–2.14)
80–89 66 (0.7) 61 (92.4) 1.36 (0.53–3.50) 1.38 (0.53–3.55) 1.38 (0.54–3.56)
Ethnicity (1HC)
White 9863 (99.3) 9012 (91.4) 1.00 1.00 1.00
Other 66 (0.7) 61 (92.4) 1.15 (0.46–2.87) 1.17 (0.47–2.91) 1.20 (0.48–3.00)
Missing 33 (0.3)
Highest educational qualification achieved (1HC)
None 3316 (33.4) 3087 (93.1) 1.00 1.00 1.00
O-Level 1090 (11.0) 1006 (92.3) 0.89 (0.69–1.15) 0.89 (0.68–1.15) 0.94 (0.72–1.22)
A-level 4110 (41.4) 3732 (90.8) 0.73 (0.62–0.87) 0.74 (0.62–0.88) 0.77 (0.64–0.91)
Degree or higher 1410 (14.2) 1246 (88.4) 0.56 (0.46–0.70) 0.57 (0.46–0.70) 0.60 (0.48–0.75)
Missing 103 (1.0)
Health characteristics
BMI category (2HC)
Underweight 41 (0.4) 35 (85.4) 0.68 (0.28–1.62) 0.65 (0.27–1.56) 0.67 (0.28–1.61)
Normal Weight 3623 (36.5) 3246 (89.6) 1.00 1.00 1.00
Overweight 4630 (46.6) 4270 (92.2) 1.38 (1.18–1.60) 1.41 (1.21–1.65) 1.40 (1.20–1.63)
Obese 1619 (16.3) 1507 (93.1) 1.56 (1.25–1.95) 1.57 (1.26–1.96) 1.54 (1.23–1.92)
Missing 16 (0.2)
Smoking status (2HC)
current smoker 739 (7.4) 693 (93.8) 1.00 1.00 1.00
former smoker 4201 (42.3) 3920 (93.3) 0.93 (0.67–1.28) 0.97 (0.70–1.33) 0.93 (0.67–1.29)
never smoked 4915 (49.5) 4393 (89.4) 0.56 (0.41–0.76) 0.55 (0.40–0.75) 0.55 (0.40–0.75)
Missing 74 (0.8)
HSV-2 serostatus†
negative 9649 (97.2) 8804 (91.2) 1.00 1.00 1.00
positive 280 (2.8) 269 (96.1) 2.35 (1.28–4.31) 2.31 (1.26–4.24) 2.32 (1.26–4.26)
Health characteristics
Country of birth (2HC, F3)
UK and Ireland 7702 (77.6) 6998 (90.9) 1.00 1.00 1.00
Other European country 96 (1.0) 92 (95.8) 2.31 (0.85–6.32) 2.28 (0.84–6.22) 2.12 (0.78–5.81)
US, Canada, Australia and NZ 40 (0.4) 38 (95.0) 1.91 (0.46–7.94) 1.92 (0.46–7.99) 1.86 (0.45–7.75)
Asia, S. America, Africa, Middle
East
99 (1.0) 91 (91.9) 1.14 (0.55–2.37) 1.11 (0.52–2.39) 1.07 (0.50–2.30)
Missing 1992 (20.1)
Level of urbanisation (1991 census data)
Urban 4536 (45.7) 4154 (91.6) 1.00 1.00 1.00
Town 2159 (21.7) 1961 (90.8) 0.91 (0.76–1.09) 0.91 (0.76–1.09) 0.91 (0.76–1.09)
(Continued)
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This is one of few studies to demonstrate that urban living and increased number of siblings
may increase the risk of HSV-1 seropositivity,[20] perhaps by increasing the opportunity for
close-contact. These factors may also reflect an overall lower socioeconomic status; having a
lower educational level, being overweight and having smoked were all associated with HSV-1
seropositivity, perhaps again reflecting lower socioeconomic status during childhood.
HSV-2 seropositivity was very strongly associated with HSV-1 seropositivity. This may be
as a result of similar behaviours putting individuals at risk of these viruses, or perhaps a genetic
predisposition to herpes simplex viruses. The association reduced significantly when defining
HSV-2 seropositivity by mgGunique alone, suggesting in our primary analyses some of the
association was due to antibody cross-reactivity. However there was still strong evidence of an
association, suggesting shared route of exposure or shared genetic predisposition.
Hypothesized factors for HSV-1 reactivation include immunosuppression[21] and there is
evidence that reactivation of other herpesviruses is more common in immunosuppressed
patients, such as those with chronic kidney disease.[25, 26] Our finding that older women with
kidney disease are at greater risk of experiencing frequent reactivation supports this
Table 3. (Continued)
Variable (source of data) Overall n
(%)
Prevalence HSV-1+ n
(%)
Unadjusted OR (95%
CI)
Fully adjusted� OR (95%
CI)
Sensitivity analysis: adjusted�� OR
(95% CI)
Village 2319 (23.4) 2121 (91.5) 0.99 (0.82–1.18) 0.99 (0.83–1.18) 1.00 (0.84–1.20)
Hamlet 910 (9.2) 832 (91.4) 0.98 (0.76–1.27) 0.98 (0.76–1.27) 1.01 (0.79–1.31)
Missing 5 (0.05)
Townsend quintile (1HC)1
Q1 (most affluent) 5667 (57.1) 5162 (91.1) 1.00 1.00 1.00
Q2 2518 (25.4) 2293 (91.1) 1.00 (0.85–1.18) 1.00 (0.85–1.17) 1.00 (0.84–1.17)
Q3 1077 (10.8) 992 (92.1) 1.14 (0.90–1.45) 1.14 (0.90–1.45) 1.14 (0.90–1.45)
Q4 553 (5.6) 516 (93.3) 1.36 (0.97–1.93) 1.35 (0.96–1.91) 1.32 (0.93–1.87)
Q5 (most deprived) 84 (0.8) 82 (97.6) 4.01 (0.98–16.36) 4.02 (0.98–16.38) 3.99 (0.98–16.28)
Missing 30 (0.3)
Number of siblings (1HC)
0 1204 (12.1) 1060 (88.0) 0.90 (0.72–1.11) 0.90 (0.72–1.11) 0.89 (0.72–1.11)
1 2398 (24.2) 2138 (89.2) 1.00 1.00 1.00
2 2141 (21.6) 1954 (91.3) 1.27 (1.04–1.55) 1.27 (1.04–1.55) 1.25 (1.03–1.53)
3 1372 (13.8) 1260 (91.8) 1.37 (1.08–1.73) 1.37 (1.08–1.72) 1.35 (1.07–1.70)
4 or more 2814 (28.3) 2661 (94.6) 2.12 (1.72–2.60) 2.12 (1.72–2.60) 2.06 (1.67–2.54)
Spent 2+ weeks in a hospital during childhood (HLEQ baseline)
No 6746 (67.9) 6143 (91.1) 1.00 1.00 1.00
Yes 1919 (19.3) 1766 (92.0) 1.13 (0.94–1.36) 1.14 (0.95–1.37) 1.13 (0.94–1.36)
Missing 1264 (12.7)
Low birth weight (1HC)
No 3897 (39.2) 3576 (91.8) 1.00 1.00 1.00
Yes (<2.5kg) 532 (5.4) 493 (92.7) 1.13 (0.80–1.60) 1.16 (0.82–1.64) 1.15 (0.81–1.63)
Missing 5500 (55.4)
�Adjusted for ethnicity and sex.
��Adjusted for ethnicity, sex, age and HSV-2 serostatus.
1Split according to cut-offs for England and Wales 1991.
1HC = First health check, 2HC = Second health check, F3 = Follow 3, HLEQ = Health and lifestyle questionnaire.
†Defined through a single antigen
https://doi.org/10.1371/journal.pone.0215553.t003
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Table 4. Description of the second cohort of HSV-1 positive patients (defined by a single antigen), prevalence of HSV reactivation and association between each var-
iable and HSV reactivation.
Overall n
(%)
Prevalence HSV
reactivation n (%)
Unadjusted OR
(95% CI)
Fully adjusted�
OR (95% CI)
Sensitivity analysis:
adjusted�� OR (95% CI)
Number of participants 7170
(100%)
887 (12.1)
Age in years (F3) 40–49 179 (2.5) 22 (12.3) 1.00 1.00 1.00
50–59 1868
(26.1)
241 (12.9) 1.06 (0.66–1.68) 1.05 (0.64–1.72) 1.12 (0.68–1.86)
60–69 2456
(34.3)
306 (12.5) 1.02 (0.64–1.61) 1.03 (0.63–1.68) 1.11 (0.67–1.83)
70–79 2120
(29.6)
263 (12.4) 1.01 (0.64–1.61) 1.09 (0.67–1.79) 1.18 (0.71–1.96)
80–89 527 (7.4) 51 (9.7) 0.76 (0.45–1.30) 0.74 (0.42–1.31) 0.79 (0.44–1.41)
Gender (1HC) Males 2854
(39.8)
330 (11.6)
Females 4316
(60.2)
557 (12.9) 1.13 (0.98–1.31) 1.10 (0.94–1.30) 1.14 (0.96–1.35)
Ethnicity (1HC) White 7123
(99.3)
883 (12.4) 1.00 1.00 1.00
Other 47 (0.7) 4 (8.5) 0.66 (0.24–1.84) 0.68 (0.21–2.26) 0.73 (0.22–2.43)
Education level (1HC) None 2305
(32.1)
299 (13.0) 1.00 1.00 1.00
O-Level 798 (11.1) 114 (14.3) 1.12 (0.89–1.41) 1.00 (0.78–1.30) 1.00 (0.77–1.29)
A-level 3003
(41.9)
363 (12.1) 0.92 (0.78–1.09) 0.89 (0.74–1.06) 0.90 (0.75–1.07)
Degree or higher 1062
(14.8)
111 (10.5) 0.78 (0.62–0.99) 0.73 (0.57–0.94) 0.75 (0.59–0.97)
Missing 2 (0.04)
Townsend quintile (1HC)1 Q1 (most
affluent)
4143
(57.8)
516 (12.5) 1.00 1.00 1.00
Q2 1809
(25.2)
224 (12.4) 0.99 (0.84–1.17) 0.96 (0.81–1.16) 0.95 (0.79–1.14)
Q3 764 (10.7) 79 (10.3) 0.81 (0.63–1.04) 0.79 (0.60–1.03) 0.77 (0.59–1.01)
Q4 383 (5.3) 59 (15.4) 1.28 (0.96–1.71) 1.30 (0.95–1.78) 1.29 (0.94–1.77)
Q5 (most
deprived)
50 (0.7) 7 (14.0) 1.14 (0.51–2.56) 1.48 (0.65–3.37) 1.60 (0.70–3.67)
Missing 13 (0.3)
Corticosteroids (F3) No 6287
(87.7)
786 (12.5) 1.00 1.00 1.00
Yes 283 (3.9) 36 (12.7) 1.02 (0.71–1.46) 0.95 (0.64–1.40) 0.90 (0.61–1.33)
Missing 434 (8.8)
Immunosuppressive medications
(F3)
No 7079
(98.7)
876 (12.4) 1.00 1.00 1.00
Yes 91 (1.3) 11 (12.1) 0.97 (0.52–1.84) 0.89 (0.44–1.80) 0.82 (0.40–1.66)
NSAIDs (F3) No 5391
(75.2)
677 (12.6) 1.00 1.00 1.00
Yes 1779
(24.8)
210 (11.8) 0.93 (0.79–1.10) 0.96 (0.80–1.15) 0.93 (0.78–1.12)
Arthritis (2HC) No 4492
(62.6)
533 (11.9) 1.00 1.00 1.00
Yes 2125
(29.6)
279 (13.1) 1.12 (0.96–1.31) 1.16 (0.98–1.39) 1.11 (0.93–1.33)
Missing 399 (8.1)
(Continued)
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Table 4. (Continued)
Overall n
(%)
Prevalence HSV
reactivation n (%)
Unadjusted OR
(95% CI)
Fully adjusted�
OR (95% CI)
Sensitivity analysis:
adjusted�� OR (95% CI)
Ulcerative Colitis / Crohn‘s Disease
(F3)
No 6634
(92.5)
826 (12.5) 1.00 1.00 1.00
Yes 104 (1.5) 15 (14.4) 1.19 (0.68–2.06) 1.16 (0.65–2.08) 1.18 (0.66–2.10)
Missing 319 (6.5)
Kidney Disease (F3) No 6680
(93.2)
828 (12.4) 1.00 1.00 1.00
Yes 87 (1.2) 17 (19.5) 1.72 (1.01–2.93) 1.81 (1.03–3.18) 1.76 (1.00–3.11)
Missing 294 (6.0)
Diabetes (2HC) No 6915
(96.4)
854 (12.3) 1.00 1.00 1.00
Yes 255 (3.6) 33 (12.9) 1.05 (0.73–1.53) 0.99 (0.65–1.50) 0.99 (0.65–1.51)
Cancer (from cancer registry data) No 6425
(89.6)
802 (12.5) 1.00 1.00 1.00
Yes 745 (10.4) 85 (11.4) 0.90 (0.71–1.15) 0.87 (0.67–1.13) 0.86 (0.66–1.13)
UV light exposure: had an outdoor
job (1HC)
No 6104
(85.1)
734 (12.0) 1.00 1.00 1.00
Yes 1063
(14.8)
152 (14.3) 1.22 (1.01–1.47) 1.30 (1.05–1.62) 1.30 (1.05–1.62)
Missing 3 (0.1)
Concentration of
25-Hydroxyvitamin D3 (nmol/L)
(2HC)
Deficient (0–29) 769 (10.7) 77 (10.0) 0.78 (0.60–1.01) 0.77 (0.58–1.03) 0.77 (0.58–1.03)
Insufficiency
(30–49)
2171
(30.3)
257 (11.8) 0.94 (0.78–1.12) 1.01 (0.83–1.22) 1.01 (0.83–1.22)
Adequate (50–69) 2337
(32.6)
293 (12.5) 1.00 1.00 1.00
High (70–89) 1273
(17.8)
183 (14.4) 1.17 (0.96–1.43) 1.21 (0.97–1.50) 1.21 (0.97–1.50)
Undesirably high
(90+)
596 (8.3) 73 (12.2) 0.97 (0.74–1.28) 1.01 (0.75–1.36) 1.01 (0.75–1.36)
Missing 18 (0.4)
Do you feel tired? (F3) All of the time 167 (2.3) 27 (16.2) 1.39 (0.91–2.13) 1.19 (0.73–1.96) 1.18 (0.72–1.94)
Most of the time 388 (5.4) 74 (19.1) 1.70 (1.29–2.24) 1.52 (1.12–2.06) 1.53 (1.13–2.07)
A good bit of the
time
778 (10.9) 111 (14.3) 1.20 (0.95–1.51) 1.09 (0.85–1.40) 1.09 (0.85–1.39)
Some of the time 2986
(41.6)
364 (12.2) 1.00 1.00 1.00
A little of the
time
2362
(32.9)
277 (11.7) 0.96 (0.81–1.13) 0.97 (0.81–1.16) 0.97 (0.81–1.16)
None of the time 411 (5.7) 30 (7.3) 0.57 (0.38–0.84) 0.58 (0.38–0.89) 0.59 (0.39–0.90)
Missing 50 (1.0)
Has stress affected your health?
(1HC)
Not at all 1970
(27.5)
206 (10.5) 1.00 1.00 1.00
A little 2693
(37.6)
347 (12.9) 1.27 (1.05–1.52) 1.26 (1.04–1.51) 1.21 (1.01–1.47)
A moderate
amount
1140
(15.9)
156 (13.7) 1.36 (1.09–1.70) 1.34 (1.07–1.68) 1.23 (0.98–1.55)
A great deal 520 (7.3) 79 (15.2) 1.53 (1.16–2.03) 1.50 (1.13–1.99) 1.34 (1.00–1.80)
Missing 599 (12.1)
(Continued)
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hypothesis. However, kidney disease was a self-reported variable, derived from a question,
“Has your doctor had ever told you that you had kidney disease (e.g. nephritis)?”, meaning it
may represent a range of mild to severe kidney disease, making interpretation of this result
more challenging. There was no evidence that any of the other comorbidities we assessed,
including arthritis, diabetes or cancer, increased susceptibility to frequent cold sores. Increased
sunlight exposure,[21, 27, 28] fatigue[21] and psychological stress[21, 29] have previously been
posited as risk factors for HSV-1 reactivation, findings which are supported in this study.
This is one of the largest population-based studies to assess childhood characteristics as risk
factors for HSV-1-seropositivity and clinical comorbidities as risk factors for oro-labial HSV
reactivation. However, there were limitations. For some of the risk factors of interest, the study
was underpowered; this may explain our null findings regarding some of the clinical comor-
bidities we assessed as risk factors for reactivation. Although the study questions addressed
here were derived following data collection, meaning the data would not be subject to recall or
reporter bias, those participants with poorer overall health may recollect illness differently to
those who are very well, potentially overestimating the associations between HSV-1 reactiva-
tion and comorbidities such as kidney disease.
Table 4. (Continued)
Overall n
(%)
Prevalence HSV
reactivation n (%)
Unadjusted OR
(95% CI)
Fully adjusted�
OR (95% CI)
Sensitivity analysis:
adjusted�� OR (95% CI)
BMI category (2HC) Underweight 25 (0.3) 3 (12.0) 0.94 (0.28–3.15) 0.75 (0.17–3.29) 0.79 (0.18–3.48)
Normal Weight 2610
(36.4)
331 (12.7) 1.00 1.00 1.00
Overweight 3383
(47.2)
400 (11.8) 0.92 (0.79–1.08) 0.91 (0.77–1.08) 0.90 (0.75–1.06)
Obese 1143
(15.9)
153 (13.4) 1.06 (0.87–1.31) 1.03 (0.83–1.29) 0.99 (0.79–1.24)
Missing 6 (0.1)
Smoking status (F3) Current smoker 502 (7.0) 51 (10.2) 0.79 (0.58–1.07) 0.71 (0.51–1.00) 0.67 (0.47–0.95)
Former smoker 3241
(45.2)
404 (12.5) 0.99 (0.86–1.15) 1.00 (0.85–1.18) 0.99 (0.84–1.16)
Never smoked 3391
(47.3)
425 (12.5) 1.00 1.00 1.00
Missing 26 (0.5)
HSV-2 infection† No 6964
(97.1)
864 (12.4) 1.00 1.00 1.00
Yes 206 (2.9) 23 (11.2) 0.89 (0.57–1.38) 0.87 (0.54–1.39) 0.87 (0.54–1.40)
Level of HSV-1 IgG, in tertiles Low 2390
(33.3)
40 (1.7) 1.00 1.00 1.00
Medium 2390
(33.3)
341 (14.3) 9.78 (7.01–13.64) 10.85 (7.52–15.66) 10.84 (7.51–15.64)
High 2390
(33.3)
506 (21.2) 15.78 (11.37–
21.89)
18.08 (12.59–
25.97)
18.28 (12.72–26.27)
Missing 33 (0.3)
�Adjusted for gender, age, ethnicity, SES, lifestyle factors (smoking and BMI) and psychological stress
��Additionally adjusted for UV light exposure, fatigue and HSV-2 status. NSAIDs: Non-steroidal anti-inflammatories. 1HC = First health check, 2HC = Second health
check, F3 = Follow 3, HLEQ = Health and lifestyle questionnaire.
†Defined through a single antigen.
1Split according to cut-offs for England and Wales 1991.
https://doi.org/10.1371/journal.pone.0215553.t004
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Another limitation is that the participation rate for the original study cohort was 39.2% and
although this cohort is similar to the general UK population[8] there is risk of bias from the
healthy participant effect, which may have led to an underestimation of both HSV-1 seroposi-
tivity and reactivation. Nevertheless, our estimates of seroprevalence concur with previous
research, suggesting this has not impacted dramatically on our findings.
The study may also have suffered from misclassification. First, reactivation was self-
reported and only measured once during the follow-up of EPIC Norfolk. However, misclassifi-
cation is likely to be non-differential according to our main exposures of interest (severe
immunosuppression and other common comorbidities of mid-late life), resulting in our esti-
mates being reduced toward the null. Additionally, outdoor job was used as a proxy for UV
exposure, as there were no data available on sunlight exposure; our results were however in
line with previous research. There may also be misclassification of our time-varying risk fac-
tors of interest, particularly from using data derived in adulthood to act as a proxy for child-
hood data, such as socioeconomic status and urban living.
As EPIC data did not specifically ask for genital HSV and serology cannot discriminate gen-
ital from non-genital HSV, we were not able to differentiate their specific risk factors, which
may differ. However, genital HSV-1 is thought to have been rare prior to the 1980s,[23, 30]
with most infection being non-genital and occurring during childhood and we therefore
assume that genital HSV-1 is rare in the EPIC Norfolk cohort.
This study has improved our understanding of the characteristics of people who are at high
risk of HSV-1 infection and frequent reactivation and will help to inform public health preven-
tion and control strategies. Our estimates provide a baseline figure which can inform future
research in this area. However, further studies are needed to understand whether clinical
comorbidities increase the risk of HSV-1 reactivation.
These data will inform research into HSV-1 in electronic healthcare data. It is likely there
will be significant under-ascertainment of HSV-1 reactivation in primary care data; the degree
of under-ascertainment can now be quantified. Our better understanding of the risk factors
for seroprevalence and reactivation of HSV-1 will also help us understand some of the poten-
tial biases and inform interpretation of the results of future studies.
Conclusions
In this large population-based study, HSV-1 seropositivity and frequent reactivation in a com-
munity dwelling ageing population is common. Lower socioeconomic status, urban living and
a greater number of siblings appear to be associated with a greater risk of HSV-1 infection.
This study showed very little evidence that common clinical comorbidities increase the risk of
orolabial HSV reactivation apart from possibly kidney disease, though the study was under-
powered for some exposures. These data will help inform studies of HSV-1.
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